FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004054136> ?p ?o ?g. }

• W3004054136 endingPage "956" @default.
• W3004054136 startingPage "947" @default.
• W3004054136 abstract "Abstract Aims Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However, there are few reports of the influence of SGLT2‐is on hepatic insulin clearance. We examined the impact of an SGLT2‐i on hepatic insulin clearance and explored the clinical influence associated with changes in hepatic insulin clearance via an SGLT2‐i and the mechanism of the effects of SGLT2‐i. Materials and methods Data were analysed from 419 patients with type 2 diabetes controlled by diet and exercise. Patients received a placebo or the SGLT2‐i tofogliflozin (TOFO) (placebo: n = 56; TOFO: n = 363) orally once daily for ≥24 weeks. Hepatic insulin clearance was calculated from the ratio of areas under the curve (AUC) of C‐peptide and insulin levels derived from oral meal tolerance test data (C‐peptide AUC 0‐120 min /insulin AUC 0‐120 min : HIC CIR ). The correlation of HIC CIR via the SGLT2‐i with other clinical variables was analysed using multivariate analysis. Results HIC CIR was significantly increased via TOFO at week 24. Furthermore, with TOFO insulin and triglyceride (TG) levels were significantly reduced ( P < 0.001) and β‐hydroxybutyrate (BHB) was significantly elevated ( P < 0.001). Changes in HIC CIR were significantly correlated with changes in TG and BHB via TOFO. Conclusions Increased HIC CIR was significantly associated with reduced TG via TOFO and contributed to the greater increase in BHB compared with placebo in addition to the correction of hyperinsulinaemia." @default.
• W3004054136 created "2020-02-07" @default.
• W3004054136 creator A5012076071 @default.
• W3004054136 creator A5025724424 @default.
• W3004054136 creator A5030118011 @default.
• W3004054136 creator A5031489668 @default.
• W3004054136 creator A5034811420 @default.
• W3004054136 creator A5036190568 @default.
• W3004054136 creator A5062390696 @default.
• W3004054136 creator A5081339326 @default.
• W3004054136 creator A5086987725 @default.
• W3004054136 date "2020-02-14" @default.
• W3004054136 modified "2023-09-24" @default.
• W3004054136 title "Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin" @default.
• W3004054136 cites W1973273635 @default.
• W3004054136 cites W1987505479 @default.
• W3004054136 cites W1996042816 @default.
• W3004054136 cites W2010174774 @default.
• W3004054136 cites W2034493672 @default.
• W3004054136 cites W2042267006 @default.
• W3004054136 cites W2048755332 @default.
• W3004054136 cites W2067507037 @default.
• W3004054136 cites W2068506660 @default.
• W3004054136 cites W2084388189 @default.
• W3004054136 cites W2107314043 @default.
• W3004054136 cites W2111946630 @default.
• W3004054136 cites W2127612701 @default.
• W3004054136 cites W2133795831 @default.
• W3004054136 cites W2140776331 @default.
• W3004054136 cites W2150391763 @default.
• W3004054136 cites W2155754561 @default.
• W3004054136 cites W2157405334 @default.
• W3004054136 cites W2163329855 @default.
• W3004054136 cites W2166304122 @default.
• W3004054136 cites W2166613497 @default.
• W3004054136 cites W2168941094 @default.
• W3004054136 cites W2170150943 @default.
• W3004054136 cites W2188955744 @default.
• W3004054136 cites W2337133379 @default.
• W3004054136 cites W2341611738 @default.
• W3004054136 cites W2412800896 @default.
• W3004054136 cites W2514898138 @default.
• W3004054136 cites W2741623958 @default.
• W3004054136 cites W2742033987 @default.
• W3004054136 cites W2773262712 @default.
• W3004054136 cites W2775295382 @default.
• W3004054136 cites W2791058787 @default.
• W3004054136 cites W2885396848 @default.
• W3004054136 cites W2888814360 @default.
• W3004054136 cites W2896997619 @default.
• W3004054136 cites W2916700999 @default.
• W3004054136 cites W2956532717 @default.
• W3004054136 doi "https://doi.org/10.1111/dom.13980" @default.
• W3004054136 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7318197" @default.
• W3004054136 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31984623" @default.
• W3004054136 hasPublicationYear "2020" @default.
• W3004054136 type Work @default.
• W3004054136 sameAs 3004054136 @default.
• W3004054136 citedByCount "7" @default.
• W3004054136 countsByYear W30040541362020 @default.
• W3004054136 countsByYear W30040541362021 @default.
• W3004054136 countsByYear W30040541362022 @default.
• W3004054136 crossrefType "journal-article" @default.
• W3004054136 hasAuthorship W3004054136A5012076071 @default.
• W3004054136 hasAuthorship W3004054136A5025724424 @default.
• W3004054136 hasAuthorship W3004054136A5030118011 @default.
• W3004054136 hasAuthorship W3004054136A5031489668 @default.
• W3004054136 hasAuthorship W3004054136A5034811420 @default.
• W3004054136 hasAuthorship W3004054136A5036190568 @default.
• W3004054136 hasAuthorship W3004054136A5062390696 @default.
• W3004054136 hasAuthorship W3004054136A5081339326 @default.
• W3004054136 hasAuthorship W3004054136A5086987725 @default.
• W3004054136 hasBestOaLocation W30040541361 @default.
• W3004054136 hasConcept C126322002 @default.
• W3004054136 hasConcept C134018914 @default.
• W3004054136 hasConcept C185592680 @default.
• W3004054136 hasConcept C2777180221 @default.
• W3004054136 hasConcept C2777391703 @default.
• W3004054136 hasConcept C2778163477 @default.
• W3004054136 hasConcept C2778199505 @default.
• W3004054136 hasConcept C2778913445 @default.
• W3004054136 hasConcept C2779306644 @default.
• W3004054136 hasConcept C555293320 @default.
• W3004054136 hasConcept C71924100 @default.
• W3004054136 hasConcept C76318530 @default.
• W3004054136 hasConceptScore W3004054136C126322002 @default.
• W3004054136 hasConceptScore W3004054136C134018914 @default.
• W3004054136 hasConceptScore W3004054136C185592680 @default.
• W3004054136 hasConceptScore W3004054136C2777180221 @default.
• W3004054136 hasConceptScore W3004054136C2777391703 @default.
• W3004054136 hasConceptScore W3004054136C2778163477 @default.
• W3004054136 hasConceptScore W3004054136C2778199505 @default.
• W3004054136 hasConceptScore W3004054136C2778913445 @default.
• W3004054136 hasConceptScore W3004054136C2779306644 @default.
• W3004054136 hasConceptScore W3004054136C555293320 @default.
• W3004054136 hasConceptScore W3004054136C71924100 @default.
• W3004054136 hasConceptScore W3004054136C76318530 @default.
• W3004054136 hasIssue "6" @default.

• next